Encompass Health (AMEX:EHC) issued an update on its FY18 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of $3.25 to $3.40 for the period, compared to the Thomson Reuters consensus estimate of $3.38. The company issued revenue guidance of $4150 to $4250, compared to the consensus revenue estimate of $4.19 billion.
Shares of Encompass Health (EHC) opened at $54.64 on Wednesday. The stock has a market cap of $5,370.00, a PE ratio of 19.94, a PEG ratio of 1.70 and a beta of 0.49. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 1.89. Encompass Health has a twelve month low of $40.86 and a twelve month high of $56.13.
Encompass Health (AMEX:EHC) last released its earnings results on Monday, February 26th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.64 by $0.06. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1 billion. Encompass Health had a net margin of 8.67% and a return on equity of 23.56%. The business’s revenue was up 7.3% on a year-over-year basis. During the same quarter last year, the business earned $0.72 EPS. research analysts expect that Encompass Health will post 2.72 earnings per share for the current fiscal year.
A number of brokerages recently weighed in on EHC. Stephens set a $62.00 price objective on shares of Encompass Health and gave the company a buy rating in a report on Tuesday. Wells Fargo & Co began coverage on shares of Encompass Health in a report on Tuesday, January 30th. They set a market perform rating and a $56.00 price objective for the company. Credit Suisse Group lifted their price objective on shares of Encompass Health from $58.00 to $61.00 and gave the company an outperform rating in a report on Tuesday. Zacks Investment Research upgraded shares of Encompass Health from a hold rating to a buy rating and set a $60.00 price objective for the company in a report on Tuesday, January 30th. Finally, Robert W. Baird reiterated a buy rating and set a $59.00 price objective on shares of Encompass Health in a report on Friday, January 12th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of Hold and an average price target of $56.20.
Encompass Health Company Profile
Encompass Health Corporation, formerly HealthSouth Corporation, is a provider of post-acute healthcare services, offering both facility-based and home-based post-acute services in 35 states and Puerto Rico through its network of inpatient rehabilitation hospitals, home health agencies and hospice agencies.
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.